Market capitalization | DKK206.32b |
Enterprise Value | DKK224.95b |
P/E (TTM) P/E ratio | 40.90 |
EV/FCF (TTM) EV/FCF | 149.87 |
EV/Sales (TTM) EV/Sales | 8.55 |
P/S ratio (TTM) P/S ratio | 7.84 |
P/B ratio (TTM) P/B ratio | 12.49 |
Dividend yield | 2.29% |
Last dividend (FY24) | DKK21.00 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
23 Analysts have issued a Coloplast A/S B forecast:
23 Analysts have issued a Coloplast A/S B forecast:
Jun '24 |
+/-
%
|
||
Revenue | 26,303 26,303 |
8%
8%
|
|
Gross Profit | 17,761 17,761 |
9%
9%
|
|
EBITDA | 8,370 8,370 |
5%
5%
|
EBIT (Operating Income) EBIT | 7,138 7,138 |
4%
4%
|
Net Profit | 4,967 4,967 |
4%
4%
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Coloplast A/S develops, manufactures, and markets medical products. It operates through the following segments: Chronic Care, Interventional Urology and Wound & Skin Care. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Interventional Urology segment covers the sale of urological products, including disposable products. The Wound & Skin Care segment covers the sale of wound and skin care products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.
Head office | Denmark |
CEO | Kristian Villumsen |
Employees | 15,692 |
Founded | 1957 |
Website | www.coloplast.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.